How long FDA expects gene therapy patients to be followed, why AAV gets up to five years and integrating vectors 15, and what Zolgensma’s tumor reports change.
Last updated: November 7, 2026
FDA’s long term follow up guidance asks sponsors to watch gene therapy patients for delayed harms like cancer: 15 years for integrating vectors such as lentiviral and gammaretroviral vectors, up to 15 years for genome editing products, and up to five years for AAV vectors, with a risk based approach allowed.
Scope: what FDA’s final 2020 long term follow up guidance requires, how durations differ by product type, and why the new Zolgensma tumor reports put AAV follow up back on the agenda.
What is long term follow up for gene therapy?
Long term follow up, or LTFU, is the structured monitoring of people who received a gene therapy, designed to catch delayed adverse events that a pivotal trial is too short to see. The main concerns are new cancers, neurologic and autoimmune disorders, blood disorders and infections.
FDA’s recommendations live in the guidance “Long Term Follow-Up After Administration of Human Gene Therapy Products,” issued as a final guidance by CBER in January 2020 (docket FDA-2018-D-2173). It finalized the July 2018 draft and replaced the 2006 guidance. It applies both in clinical trials and, in many cases, after approval.
How long does FDA require gene therapy patients to be followed?
The duration depends on how the product behaves in the body. The guidance sets 15 years for vectors that integrate into the genome and up to five years for AAV vectors, with up to 15 years for products that can stay latent, cause persistent infection or edit the genome.
| Product type | Recommended LTFU duration | Main delayed risk |
|---|---|---|
| Integrating vectors (gammaretroviral, lentiviral, transposon elements) | 15 years | Insertional cancer |
| Genome editing products | Up to 15 years | Off target edits, cancer |
| Herpes virus vectors or oncolytics capable of latency | Up to 15 years | Reactivation |
| Microbial vectors known to persist | Up to 15 years | Persistent infection |
| AAV vectors | Up to 5 years | Prolonged expression; integration considered low |
Source: FDA, Long Term Follow-Up After Administration of Human Gene Therapy Products, January 2020, section V.C. Table compiled by BioMed Nexus.
The guidance also allows a risk based approach to setting duration for latent vectors, for vectors that drive long expression without integrating (AAV is the example) and for vectors that carry gene editing components. In FDA’s own risk table, AAV is classed as not having a propensity to modify the genome, with LTFU described as product specific.
Why does FDA treat AAV differently from lentiviral vectors?
Because AAV mostly stays outside the chromosomes as an episome, while lentiviral and gammaretroviral vectors insert themselves into the host genome by design. Integration can switch on a cancer gene near the insertion site, which is the risk 15 year follow up exists to catch.
FDA’s risk factors for delayed events are integration activity, genome editing activity, prolonged expression of the transgene, latency and persistent infection. AAV checks only the prolonged expression box under the 2020 framework. That is why the shorter window was a reasonable default, and also why any evidence of AAV integration in patients matters so much.
What did Novartis report about Zolgensma and tumors?
On November 5, 2026, Novartis disclosed tumor cases in people with spinal muscular atrophy treated with Zolgensma (onasemnogene abeparvovec), an AAV gene therapy. BioPharma Dive reported nine people developed tumors and that two cases showed evidence the vector DNA had integrated into patient DNA. Endpoints described seven of the cases as new.
According to BioPharma Dive, Novartis said it notified health authorities after each case and “will continue to work with them on next steps,” and that more than 6,000 people have received the therapy. Cure SMA said three of the nine tumors were tested and one appears unrelated to Zolgensma. We have not seen a Novartis press release or a published case series with tumor types, so those details are not printed here.
The current label already carries the risk. Section 5.6, “AAV Vector Integration and Risk of Tumorigenicity,” states there is “a theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome,” that tumor cases have been reported after approval, and that “a causal relationship with ZOLGENSMA has not been established based on tumor analyses.” The boxed warning is about serious liver injury and acute liver failure. Zolgensma was approved in May 2019 for children under 2 with SMA caused by mutations in both copies of the SMN1 gene.
What does a long term follow up protocol actually include?
A dedicated protocol with a visit schedule, a sampling plan, defined tests and a list of clinical events of interest, with contact at least once a year. The first five years are the most intensive.
| Element | What the guidance recommends |
|---|---|
| Baseline | Medical history and exposure records, including mutagenic agents and other medicines |
| Contact | At least once a year for the full duration |
| Years one to five | Annual physical exam by a health care provider, labs such as a hematology profile, recording of new cancers and neurologic, autoimmune, hematologic and infectious events |
| Vector persistence | At least annual testing for vector sequences until they become undetectable |
| Integrating vectors | Integration site testing at least every six months for five years, then at least yearly for ten more years |
| Causality | Analysis of each event, with tissue or autopsy sampling where needed |
Does follow up continue after FDA approval?
Often, yes. The guidance says continuing LTFU observations “is often essential even after a product’s licensure,” and asks for a pharmacovigilance plan with the BLA. FDA may recommend a new or existing patient registry, and may consider a REMS during review.
This is where the hard work sits for commercial products. A trial site can compel visits. A commercial program has to keep thousands of treated patients, many of them infants who will change doctors, states and insurers, connected to a registry for years. The Zolgensma cases came from post approval reporting across a treated population of more than 6,000, which is exactly the scale at which rare delayed events show up. For background on how filings are structured, see our explainer on IND, NDA and BLA filings.
Could AAV follow up requirements get longer?
Possibly, but FDA has not said so. The 2020 guidance is still the current final version on fda.gov as far as we can find, and it already lets FDA push AAV durations up on a product specific basis.
Two integration linked cases in an AAV population would be the kind of evidence a risk based approach responds to. The practical levers are label language, registry requirements for approved products and longer protocols for new AAV programs, especially those using high systemic doses. Sponsors planning AAV programs today should budget as if five years is a floor rather than a ceiling.
Our framework: an LTFU readiness checklist for sponsors
- Classify the product honestly: integrating, editing, latent, persistent or AAV. Document why, using FDA’s risk factors.
- Budget the tail: LTFU is often the longest running cost in a gene therapy program. Model it for the full duration and for a commercial registry, not just the trial.
- Keep samples: bank tissue and blood so integration analysis is possible if a tumor appears. The Zolgensma cases show causality questions depend on having material to test.
- Plan for retention: pediatric patients move. Build consent, contact and registry systems that survive changes in doctors and payers.
- Write the tumor response plan now: who tests, which lab runs integration site analysis, how fast health authorities are told.
- Watch your vendors: confirm your CDMO and CRO can support integration assays and 15 year data retention. Our guide on choosing a gene and cell therapy CDMO covers what to ask.
What to watch next
- Any Zolgensma label update, Dear health care provider letter or FDA safety communication.
- A published case series with tumor types and integration analyses.
- Whether regulators extend scrutiny to Itvisma, which shares the active ingredient onasemnogene abeparvovec.
- Whether FDA revises the 2020 guidance or applies longer AAV follow up to new programs.
FAQ
How many years of follow up does FDA require after gene therapy?
Fifteen years for integrating vectors, up to 15 years for genome editing, latent and persistent vectors, and up to five years for AAV vectors, under FDA’s January 2020 guidance.
Is FDA’s long term follow up guidance final?
Yes. CBER finalized it in January 2020, replacing the July 2018 draft and the 2006 guidance.
Why do AAV gene therapies get shorter follow up?
AAV vectors are not considered to have a propensity to integrate into the genome, so FDA’s default is up to five years, with a risk based approach allowed.
Can AAV integrate into human DNA?
Rarely, and the Zolgensma label already describes a theoretical tumor risk from integration. Trade reports say two of nine recent tumor cases showed evidence of integration.
How many Zolgensma tumor cases were reported?
BioPharma Dive reported nine, with two showing evidence of vector integration. Novartis has not published tumor types in a release we could find.
Has a causal link between Zolgensma and cancer been established?
The label states a causal relationship has not been established based on tumor analyses. Cure SMA said one tested tumor appears unrelated.
What is Zolgensma’s boxed warning?
Serious liver injury and acute liver failure, including fatal cases. The label asks for liver function monitoring for at least three months after infusion.
What does long term follow up include?
At least yearly contact, annual exams and labs for the first five years, tracking of cancers and other delayed events, and testing for vector persistence.
Does follow up continue after approval?
Often. FDA says continued observation is often essential after licensure and may recommend a patient registry.
Who pays for long term follow up?
The sponsor runs and funds LTFU studies and registries, which makes them a significant long term program cost.
Sources
- FDA, Long Term Follow-Up After Administration of Human Gene Therapy Products, Guidance for Industry, January 2020 (primary)
- FDA, Zolgensma prescribing information, revised June 2026, and Zolgensma product page (primary)
- FDA, Approved Cellular and Gene Therapy Products list (primary)
- BioPharma Dive, Jonathan Gardner, November 6, 2026 (case counts, Novartis statement, Cure SMA testing; attributed)
- Endpoints News, November 5, 2026 (seven new cases; attributed)
Related coverage
- Gene therapy vs cell therapy vs gene editing
- FDA accelerated approval and confirmatory trial rules explained
- Artiva ends AlloNK autoimmune cell therapy after two deaths
- How to choose a gene and cell therapy CDMO
- IND, NDA and BLA: the FDA filings explained
- The BioMed Nexus directory
Get this kind of analysis every morning: subscribe to BioMed Nexus.
